No connection

Search Results

CWK

BEARISH
$14.35 Live
Cushman & Wakefield Limited · NYSE
$8.66 52W Range $17.4
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$3.36B
P/E
37.76
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
The deterministic health baseline is critical, with a Piotroski F-Score of 0/9 indicating severe financial distress or fundamental deterioration. While the company shows strong earnings growth and a favorable PEG ratio of 0.65, these are overshadowed by a complete failure in health metrics and a bearish technical trend. The stark contrast between the Forward P/E (8.47) and the current P/E (37.76) suggests high growth expectations that are not supported by the current balance sheet health. Consequently, the stock is viewed as high-risk despite recent earnings beats.

Key Strengths

Strong earnings surprise track record (3/4 beats in last 4 quarters)
Attractive PEG ratio of 0.65 suggesting undervaluation relative to growth
Significant Q/Q EPS growth of 86.2%
Low Forward P/E (8.47) compared to trailing P/E
Strong 1-year price appreciation of 60.2%

Key Risks

Critical financial health failure (Piotroski F-Score 0/9)
Bearish insider sentiment with net selling activity
Bearish technical trend (0/100 score)
High trailing P/E ratio of 37.76
Lack of dividend support and missing liquidity metrics (Current/Quick ratios)
AI Fair Value Estimate
Based on comprehensive analysis
$11.5
-19.9% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
33
Weak
Value
50
Future
75
Past
40
Health
0
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 0/9, Strong EPS growth, Bearish technicals, Low PEG ratio
Confidence
80%
Value
50/100

Valuation is split between a high trailing P/E and a very attractive forward-looking PEG.

Positives
  • Low PEG ratio
  • Low Forward P/E
Watchpoints
  • High trailing P/E
  • Price/Book at 1.70
Future
75/100

Growth metrics are the only bullish driver in the dataset.

Positives
  • Consistent earnings beats
  • Strong Q/Q EPS growth
Watchpoints
  • Uncertainty regarding balance sheet sustainability
Past
40/100

Short-term momentum is positive, but long-term performance is lagging.

Positives
  • Strong 1Y and 3Y price returns
Watchpoints
  • Negative 5Y change (-15.4%)
  • Recent 6M decline (-16%)
Health
0/100

The 0/9 F-Score is a definitive signal of weak financial health.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
Dividend
0/100

Company provides no income return to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend yield
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$14.35

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CWK and closest competitors.

Updated 2026-04-24
CWK
Cushman & Wakefield Limited
Primary
5Y
-15.4%
3Y
+57.5%
1Y
+60.2%
6M
-16.0%
1M
+17.8%
1W
-1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
37.76
Forward P/E
8.47
PEG Ratio
0.65
P/B Ratio
1.7
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$3.36B

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin N/A
Gross Margin N/A
ROE N/A
ROA N/A

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth +10.81%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
N/A
Quick Ratio
N/A
Cash/Share
$N/A

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$2.9B
Gross Margin
19.7%
Op. Margin
6.1%
Net Margin
-0.8%
Total Assets
$7.7B
Liabilities
$5.7B
Equity
$2.0B
Debt/Equity
2.93x
Operating CF
$0.3B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
91%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-19
$0.54
+0.3% surprise
2025-10-30
$0.29
+4.3% surprise
2025-08-05
$0.3
+36.7% surprise

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

ROBINSON NATHANIEL B
Chief Investment Officer
Sell
2026-03-03
10,000 shares · $135,000
MACKAY MICHELLE M
Chief Executive Officer
Stock Award
2026-02-27
101,540 shares
JOHNSTON NEIL O
Chief Financial Officer
Stock Award
2026-02-27
30,812 shares
ROBINSON NATHANIEL B
Officer
Stock Award
2026-02-27
14,005 shares
PERKINS NOELLE J
Officer
Stock Award
2026-02-27
15,406 shares
MCDONALD ANDREW R
Chief Operating Officer
Stock Award
2026-02-27
53,921 shares
SAYED LAURIDA CPA
Officer
Stock Award
2026-02-27
5,602 shares
MACKAY MICHELLE M
Chief Executive Officer
Stock Award
2026-02-25
202,877 shares
JOHNSTON NEIL O
Chief Financial Officer
Stock Award
2026-02-25
146,337 shares
ROBINSON NATHANIEL B
Chief Investment Officer
Stock Award
2026-02-25
53,213 shares
MCDONALD ANDREW R
Officer
Stock Award
2026-02-25
186,249 shares
MACKAY MICHELLE M
Chief Executive Officer
Stock Award
2026-02-23
37,992 shares
JOHNSTON NEIL O
Chief Financial Officer
Stock Award
2026-02-23
27,405 shares
ROBINSON NATHANIEL B
Chief Investment Officer
Stock Award
2026-02-23
9,966 shares
MCDONALD ANDREW R
Chief Operating Officer
Stock Award
2026-02-23
34,878 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-08

CWK filed an 8-K on April 8, 2026, likely to announce its first-quarter financial results.

DEF 14A
DEF 14A
2026-04-03

CWK filed a definitive proxy statement on April 3, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

8-K
8-K
2026-02-19

CWK filed an 8-K on February 19, 2026, likely to announce its fourth-quarter and full-year financial results.

10-K
10-K
2026-02-19

CWK filed its annual 10-K report on February 19, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures, though they identify the relevant sections for business operations and management's analysis.

8-K
8-K
2025-12-04
10-Q
10-Q
2025-10-30

CWK filed its 10-Q on October 30, 2025, though the provided excerpt contains no specific financial highlights. The filing includes a section on Risk Factors under Item 1A, but detailed risk descriptions were not included in the available text.

8-K
8-K
2025-10-30

CWK filed an 8-K on October 30, 2025, likely to report its third-quarter financial results.

8-K
8-K
2025-10-21

CWK filed an 8-K on October 21, 2025, likely to report its third-quarter financial results.

8-K
8-K
2025-10-16

CWK filed an 8-K on October 16, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-10-02

CWK filed an 8-K on October 2, 2025, likely to announce its third-quarter financial results.

DEF 14A
DEFINITIVE PROXY STATEMENT
2025-09-04
8-K
8-K
2025-08-05
10-Q
10-Q
2025-08-05
8-K
8-K
2025-07-21
8-K
8-K
2025-06-23
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Barclays
2026-03-13
Maintains
Equal-Weight Equal-Weight
Barclays
2025-12-02
init
Equal-Weight
Citigroup
2025-11-21
up
Neutral Buy
Citigroup
2025-11-12
Maintains
Neutral Neutral
Citizens
2025-11-03
Maintains
Market Outperform Market Outperform

Past News Coverage

Recent headlines mentioning CWK from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile